# BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Source: https://onco.cc/trials/nct05322590/  
OnCo record `nct05322590` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BXQ-350 in colorectal cancer, run by Bexion Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma is a phase 1/2 interventional study registered as NCT05322590 by Bexion Pharmaceuticals, Inc., with 195 participants enrolled, started 2023-01-09 and due to reach its primary completion in 2026-04. Interventions recorded: BXQ-350.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05322590
- Phase: 1/2
- Setting: A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination With mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma
- Sponsor: Bexion Pharmaceuticals, Inc.
- Enrolled: 195

## Sources

- ClinicalTrials.gov NCT05322590: https://clinicaltrials.gov/study/NCT05322590

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- companies: [ICON plc](https://onco.cc/companies/icon-plc/)

---
JSON: https://onco.cc/api/v1/entities/nct05322590.json